Loading
CodeLab Capital AS Stock: price and insider trades · Norway
No insider purchase over the last 90 days. The latest was filed 01 Jun 2026.
CodeLab Capital AS: what insiders have been doing
Every trade that managers of CodeLab Capital AS disclose to Oslo Børs is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 4 filings signed by 3 insiders.
Every open-market trade in the period is a purchase: 3 purchases worth €13, from 2 insiders, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €6 from Lorenz AS, disclosed on 16 January 2026.
The latest purchase dates back some time: it was published 138 days ago, on 1 June 2026.
Compared with its exchange (258 companies, median 4 filings), a count of 4 filings is typical. Since 2021, the database holds 26 purchases and 3 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from Oslo Børs disclosures alone and does not predict where the share price will go.
Insider Decl.
39
Thresholds
n/a
Buy Volume
€8M
26 ops. · all time
Sell Volume
€103,576
3 ops. · all time
Who traded when
BuySaleLorenz AS5 buys
Codee Holding AS1 buy1 sale
KI Holding1 buy
Since the insiders bought
- +55.2%Entry NOK 3.30 · Close 16 Oct 2026 NOK 5.12
- -33.3%Entry NOK 4.20 · Close at T+365 NOK 2.80
- +3.8%Entry NOK 2.35 · Close at T+365 NOK 2.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 19,719 of 24,158 companies
29.6
score / 100
Value13
Quality46
FCF yld-13%
Earn yld-14%
EV/EBITDA·
ROE-47%
Gross mgn67%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NOK 5.20
Analyst consensus
Income statement
RevenueNOK 10.7M
Gross profitNOK 7.1M67% margin
EBITDA-NOK 12.1M-113% margin
Net income-NOK 14.9M-51.8% margin
Valuation
P/Book2.6x
Beta0.68
Balance sheet & cash
Market capNOK 102.7M
Total debtNOK 3.4M
Free Cash Flow-NOK 13.2M
Debt / Equity8%
Profitability & ownership
ROE-47.5%
ROA-20.9%
% insiders62.2%
% institutions0.0%
Last declaration on 1 June 2026
Declarations39 total
605,696 shares@ NOK 3.30100.0% of flowShareXOAMOSLO:658499
8.5 shares@ NOK 34,990.00100.0% of flowShareXOAMOSLO:640910
Canonical exit: 9 Jun 2025 (T+90)
25,821,551 shares@ NOK 0.04421.6% of flowShareXOAMOSLO:637232
Canonical exit: 27 Apr 2025 (T+90)
102,538,117 shares@ €0.08510.0% of flowShareXOAMOSLO:637049
16,821,551 sharesShareXOAMOSLO:623957
Canonical exit: 20 Oct 2024 (T+90)
ShareXOAMOSLO:613152
1,300,000 shares@ €559.4873.5% of flowShareXOAMOSLO:601733
Canonical exit: 17 Jan 2024 (T+90)
542.854 shares@ NOK 7,942.006.0% of flowShareXOAMOSLO:601164
Canonical exit: 9 Jan 2024 (T+90)
457.146 shares@ NOK 6,283.004.0% of flowShareXOAMOSLO:601140
Canonical exit: 8 Jan 2024 (T+90)
24,505,772 sharesShareXOAMOSLO:590792
Canonical exit: 13 Aug 2023 (T+90)
14,604,676 shares@ NOK 0.509.9% of flowShareXOAMOSLO:589360
ShareXOAMOSLO:585961
Canonical exit: 21 Jun 2023 (T+90)
25 of 39 declarations
About CodeLab Capital AS
CodeLab Capital AS is a company focused on the health and pharmaceutical sector. It is listed on the XOSL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
